EMA’s PRIME Process Could Be A Model For Tackling Pediatric Development Issues, Says Industry
The EMA can learn from its existing processes to ensure that the EU Paediatric Regulation is implemented in a way that fits more naturally with the industry's product development process and allows for improved dialogue, EFPIA has suggested.
You may also be interested in...
A wide-range of stakeholders at a European Medicines Agency workshop on how to improve the implementation of the EU Paediatric Regulation offered practical solutions to address the current shortcomings.
The International Pharmaceutical Regulators Programme has documented various approaches currently being used for the clinical comparability of biosimilar monoclonal antibodies in different jurisdictions.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.